Prostate Cancer Research

Androgen receptor (AR) signalling and drug resistance in prostate cancer

Androgen receptor (AR) signalling and drug resistance in prostate cancer

The androgen receptor (AR) is a key protein in prostate cells that binds androgen sex hormones (e.g. testosterone) that drive prostate cancer development and progression. We are leading research developing and trialling new androgen receptor targeted drugs to combat drug resistance and fatal disease.

The University of Adelaide
Contact:
Professor Lisa Butler, Associate Professor Luke Selth